Epirubicin
Renal Neoplasm
Syndax PharmaceuticalsPhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 89/ 100
Competitive context
5 Active assets in the Renal Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Oxycodone University of Miami | Phase 2 | CCC |
IBUPROFEN University of Miami | Phase 2 | CCC |
HYDROMORPHON University of Miami | Phase 2 | CCC |
Ketorolac Tromethamine University of Miami | Phase 2 | CCC |
Entinostat Syndax Pharmaceuticals | Phase 1 | CCC |
pf-08634404 Pfizer | Phase 1/2 | CC |
Pembrolizumab Syndax Pharmaceuticals | Phase 1 | CC |
MUBRITINIB Takeda | Phase 1 | CC |
Same molecule, other indications
Epirubicin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →